Literature DB >> 6518249

Exact significance testing to establish treatment equivalence with ordered categorical data.

C R Mehta, N R Patel, A A Tsiatis.   

Abstract

This communication concerns the problem of establishing the therapeutic equivalence of two treatments that are being compared on the basis of ordered categorical data. The problem is formulated as a significance test in which the null hypothesis specifies a treatment difference. An efficient numerical algorithm for computing the exact significance level is provided, along with a simple method for obtaining the asymptotic significance level. Both methods are applied to a clinical trial of a new agent versus an active control. Guidelines for when to use the exact procedure and when to rely on asymptotic theory are provided.

Mesh:

Year:  1984        PMID: 6518249

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  43 in total

1.  Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group.

Authors:  Athanassios Argiris; Ashley Buchanan; Bruce Brockstein; Jill Kolesar; Musie Ghebremichael; Michael Pins; Kristine Hahn; Rita Axelrod; Arlene Forastiere
Journal:  Cancer       Date:  2009-10-01       Impact factor: 6.860

2.  Cardio-vascular safety beyond hERG: in silico modelling of a guinea pig right atrium assay.

Authors:  Luca A Fenu; Ard Teisman; Stefan S De Buck; Vikash K Sinha; Ron A H J Gilissen; Marjoleen J M A Nijsen; Claire E Mackie; Wendy E Sanderson
Journal:  J Comput Aided Mol Des       Date:  2009-11-05       Impact factor: 3.686

3.  Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890).

Authors:  Janice P Dutcher; Jason P Fine; Robert L Krigel; Barbara A Murphy; Paul L Schaefer; Marc S Ernstoff; Patrick J Loehrer
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

4.  Phase III study of combined chemohormonal therapy in metastatic prostate cancer (ECOG 3882): an Eastern Cooperative Oncology Group study.

Authors:  Andrea N Leaf; Kathleen Propert; Chris Corcoran; Paul J Catalano; Donald L Trump; Jules E Harris; Thomas E Davis
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

5.  Comparison of clinical and pathological staging in head and neck squamous cell carcinoma: results from Intergroup Study ECOG 4393/RTOG 9614.

Authors:  Wayne M Koch; John A Ridge; Arlene Forastiere; Judith Manola
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2009-09

6.  Speckle myocardial imaging modalities for early detection of myocardial impairment in isolated left ventricular non-compaction.

Authors:  Diego Bellavia; Hector I Michelena; Matthew Martinez; Patricia A Pellikka; Charles J Bruce; Heidi M Connolly; Hector R Villarraga; Gabriella Veress; Jae K Oh; Fletcher A Miller
Journal:  Heart       Date:  2009-12-04       Impact factor: 5.994

7.  Response of Iron Deficiency Anemia to Intravenous Iron Sucrose in Pediatric Inflammatory Bowel Disease.

Authors:  Istvan Danko
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Mar-Apr

8.  Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197.

Authors:  Lori J Goldstein; Anne O'Neill; Joseph A Sparano; Edith A Perez; Lawrence N Shulman; Silvana Martino; Nancy E Davidson
Journal:  J Clin Oncol       Date:  2008-08-04       Impact factor: 44.544

9.  Reducing the cesarean section rate in a rural community hospital.

Authors:  S Iglesias; R Burn; L D Saunders
Journal:  CMAJ       Date:  1991-12-01       Impact factor: 8.262

10.  Contemporary risk profile of prostate cancer in the United States.

Authors:  Yu-Hsuan Shao; Kitaw Demissie; Weichung Shih; Amit R Mehta; Mark N Stein; Calpurnyia B Roberts; Robert S Dipaola; Grace L Lu-Yao
Journal:  J Natl Cancer Inst       Date:  2009-08-27       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.